Back to Search
Start Over
mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
- Source :
-
Gynecologic oncology [Gynecol Oncol] 2020 Nov; Vol. 159 (2), pp. 554-562. Date of Electronic Publication: 2020 Sep 18. - Publication Year :
- 2020
-
Abstract
- Objective: Mutations in the MAP kinase pathway (KRAS, NRAS, BRAF) are common in low grade serous ovarian carcinoma (LGSOC). The effect of these and other mutations on RNA transcription in this disease is poorly understood. Our objective was to describe patterns of somatic mutations and gene transcription in a racially diverse population with LGSOC.<br />Methods: Utilizing an institutional tumor registry, patients with LGSOC were identified and charts were reviewed. RNA was extracted from available tumor tissue. Commercial tumor profiling results were analyzed with PanCancer pathway nanoString mRNA expression data. Along with nanoString n-Solver software, Chi-squared, Fishers Exact, and Cox proportional hazards models were used for statistical analysis, with significance set at p < 0.05.<br />Results: 39 patients were identified-20% Black, 43% Hispanic, and 36% non-Hispanic White. 18 patients had commercial somatic DNA test results, and 23 had available tumor tissue for RNA extraction and nanoString analysis. The most common somatic alterations identified was KRAS (11 patients, 61%), followed by ERCC1 and TUBB3 (9 each, 50%). KRAS mutations were less common in smokers (14.3% vs 90.9%, p = 0.002). RNA expression analysis demonstrated a greater than two-fold decrease in expression of HRAS in tumors from older patients (p = 0.04), and a greater than two-fold decrease in the expression of HRAS in recurrent tumors (p = 0.007). No significant differences were seen in somatic testing results, RNA expression analysis, or progression free survival between different racial and ethnic cohorts.<br />Conclusions: Somatic deficiencies in ERCC1, TUBB3, and KRAS are common in LGSOC in a population of minority patients. HRAS demonstrates decreased expression in tumors from older patients and recurrent tumors.<br />Competing Interests: Declaration of Competing Interest BMS serves on advisory boards for GOG Foundation, Astra Zeneca, AbbVie, Clovis, GSK, Genentech, and Myriad. MH is supported in unrelated research by grants from Merck and Jansen, and serves on advisory boards for Clovis and GSK. The remaining authors have no relevant conflicts of interest to disclose.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Biomarkers, Tumor genetics
Cystadenocarcinoma, Serous ethnology
Cystadenocarcinoma, Serous pathology
Female
Gene Expression Profiling methods
Germ-Line Mutation
Humans
Middle Aged
Ovarian Neoplasms ethnology
Ovarian Neoplasms pathology
Progression-Free Survival
Proto-Oncogene Proteins p21(ras)
Registries
Retrospective Studies
Tubulin
Xeroderma Pigmentosum Group D Protein
Young Adult
Cystadenocarcinoma, Serous genetics
Ovarian Neoplasms genetics
RNA, Messenger analysis
Subjects
Details
- Language :
- English
- ISSN :
- 1095-6859
- Volume :
- 159
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Gynecologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 32951896
- Full Text :
- https://doi.org/10.1016/j.ygyno.2020.08.030